Rep. Josh Gottheimer Purchases Shares of Insmed, Inc. (NASDAQ:INSM)

Key Points

• Representative Josh Gottheimer purchased between $1,001 and $15,000 of Insmed, Inc. (NASDAQ:INSM) stock on June 16th, as disclosed in a filing.
• Insmed's stock recently traded at $104.01, showing a 0.5% increase, with a market capitalization of $19.73 billion.
• The biopharmaceutical company reported a quarterly earnings miss, with EPS at ($1.42), below analysts' expectations, but revenue increased by 22.9% year-over-year.
• A number of analysts have raised their price targets for Insmed, with forecasts ranging from $90.00 to $120.00, reflecting positive market sentiment.

Representative Josh Gottheimer (D-New Jersey) recently bought shares of Insmed, Inc. NASDAQ: INSM. In a filing disclosed on July 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in Insmed stock on June 16th. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 6/25/2025.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 6/25/2025.
• Sold $1,001 - $15,000 in shares of ConocoPhillips NYSE: COP on 6/24/2025.
• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 6/24/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 6/24/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 6/20/2025.
• Purchased $1,001 - $15,000 in shares of Cloudflare NYSE: NET on 6/20/2025.
• Purchased $1,001 - $15,000 in shares of Carvana NYSE: CVNA on 6/20/2025.
• Sold $1,001 - $15,000 in shares of McDonald's NYSE: MCD on 6/20/2025.

Insmed Stock Performance

INSM stock traded up $2.08 during midday trading on Tuesday, hitting $103.83. 721,518 shares of the company traded hands, compared to its average volume of 2,745,725. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $106.83. The company has a quick ratio of 5.44, a current ratio of 5.86 and a debt-to-equity ratio of 11.38. The business has a 50 day simple moving average of $91.25 and a 200-day simple moving average of $80.16. The stock has a market capitalization of $19.70 billion, a price-to-earnings ratio of -17.44 and a beta of 0.90.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The company had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. The company's revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.06) EPS. As a group, equities research analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current year.

Wall Street Analyst Weigh In

INSM has been the subject of several analyst reports. JPMorgan Chase & Co. boosted their target price on Insmed from $90.00 to $111.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 8th. Bank of America increased their price objective on Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a research report on Wednesday, June 11th. Leerink Partners increased their price objective on Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 10th. Citigroup upgraded Insmed to a "buy" rating in a research report on Tuesday, June 10th. Finally, Royal Bank Of Canada increased their price objective on Insmed from $99.00 to $106.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 11th. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $109.20.

Insider Buying and Selling

In related news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the company's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the completion of the sale, the insider owned 89,407 shares in the company, valued at approximately $8,352,401.94. This represents a 52.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Sara Bonstein sold 58,400 shares of the business's stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $102.67, for a total value of $5,995,928.00. Following the sale, the chief financial officer directly owned 73,505 shares of the company's stock, valued at $7,546,758.35. This represents a 44.27% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 606,597 shares of company stock valued at $55,120,762 in the last 90 days. 3.00% of the stock is owned by insiders.

Institutional Trading of Insmed

A number of institutional investors have recently added to or reduced their stakes in the stock. Cullen Frost Bankers Inc. increased its position in shares of Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 221 shares during the last quarter. Elequin Capital LP bought a new position in Insmed during the 4th quarter worth approximately $28,000. ORG Partners LLC grew its position in Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 196 shares during the last quarter. Hilltop National Bank bought a new position in Insmed during the 2nd quarter worth approximately $28,000. Finally, Steward Partners Investment Advisory LLC grew its position in Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 163 shares during the last quarter.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election. Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.